High Bioavailability Resveratrol Delivery System: A Novel Nutritional Strategy for the Prevention and Alleviation of Rheumatoid Arthritis

ABSTRACT This study aimed to develop an oral solid dispersion nutrient delivery system of resveratrol (RSV) and Eudragit E PO (E PO) for the prevention of rheumatoid arthritis. The RSV‐E PO solid dispersion, prepared by the solvent method at a drug—polymer ratio of 1:7 (w/w), turned resveratrol into an amorphous state, as proved by SEM, DSC, XRD, and FTIR. Over 80% of resveratrol was released in vitro, a 13‐fold increase compared to raw resveratrol. In male Sprague—Dawley rats, its oral administration (20 mg·kg −1 ) doubled bioavailability versus unformulated resveratrol. Evaluated in an adjuvant‐induced arthritis (AIA) model, the compound demonstrated significant anti‐arthritic effects. These protective effects were primarily mediated through the modulation of key inflammatory and oxidative stress pathways, as evidenced by a marked reduction in pro‐inflammatory cytokines (IL‐6, TNF‐α, IL‐1β) and malondialdehyde (MDA) levels, coupled with an increase in the anti‐inflammatory cytokine IL‐10 and the antioxidant enzyme superoxide dismutase (SOD). Also, its safety was confirmed by stable AST, ALT, CREA, and BUN levels. In summary, the RSV‐E PO solid dispersion, with better dissolution and bioavailability, serves as an effective oral nutrient delivery system for RSV.